Stockscreener 앱 받기
13.29
0.68%
0.09
시간 외 거래:
13.20
-0.09
-0.68%
Viatris Inc 주식(VTRS)의 최신 뉴스
[144] Viatris Inc SEC Filing - Stock Titan
Barclays raises Viatris stock price target on pipeline potential - Investing.com
Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder - Contract Pharma
Barclays Adjusts Viatris Price Target to $17 From $15, Maintains Overweight Rating - marketscreener.com
Viatris Stock: Is VTRS Outperforming the Health Care Sector? - Barchart
Viatris Says Japan Regulator Approves Effexor for Generalized Anxiety Disorder in Adults - marketscreener.com
Viatris wins Japan approval for Effexor to treat anxiety disorder - Investing.com
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) - PR Newswire
Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline - The National Law Review
How (VTRS) Movements Inform Risk Allocation Models - Stock Traders Daily
What are analysts saying about Viatris Inc (VTRS) stock? - MSN
Viatris shares break six-session winning streak - MSN
Viatris sets long-term targets ahead of investor event - MSN
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Theravance's Q4 Earnings and Revenues Miss Estimates - TradingView
Viatris: Is It A Credible Turnaround Or Overly Optimistic 2030 Plan? - Seeking Alpha
Will Viatris’ 2030 Capital and R&D Framework Reset the Core Investment Narrative for VTRS? - simplywall.st
VTRS Stock Price, Quote & Chart | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris sets revenue growth targets through 2030 By Investing.com - Investing.com India
Viatris sets revenue growth targets through 2030 - Investing.com
Viatris : VTRS Investor Event Presentation FINAL (1) - marketscreener.com
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 - PR Newswire
Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022. - marketscreener.com
Class Action Filed Against Viatris Inc. (VTRS) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review
Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drug pipeline - MSN
Antiretroviral Therapy Market Critical Analysis with Expert Opinion| Gilead Sciences, Viatris, AbbVie - openPR.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - MSN
Viatris Inc. stock rises Monday, outperforms market - MSN
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
What Are Analysts Saying About Viatris Inc (VTRS) Stock? - Insider Monkey
Henrietta Lacks family settles lawsuit against Viatris over cell use - WBFF
Assessing Viatris (VTRS) Valuation After Mixed Short And Long Term Share Price Moves - Yahoo Finance
UBS and BofA Lift Price Targets on Viatris (VTRS) - Insider Monkey
Assessing Viatris (VTRS) Valuation After Recent Share Price Pullback - simplywall.st
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal - MSN
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research - Reuters
Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit - marketscreener.com
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst - TipRanks
Novo, Mylan Seek Judgment on Key Wegovy Patent Before Trial - Bloomberg Law News
Viatris resolves case over use of woman’s cancer cells to advance drug research - Seeking Alpha
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
Viatris Collaborates With GoodRx for Discounts of Up to 85% on Medications - marketscreener.com
Lipitor and Viagra discounts: GoodRx deal cuts brand drugs to $0–$4 - Stock Titan
Viatris Stock Analysis: Strong 6-Month Gains vs. Poor 5-Year FundamentalsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Trading Systems Reacting to (VTRS) Volatility - Stock Traders Daily
Propranolol Market Overall Study Report 2026-2033 | Teva - openPR.com
Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Viatris (VTRS) CCO granted RSUs, settles prior units and tax withholdings - Stock Titan
Viatris (VTRS) CFO adds 86,017 RSUs and withholds shares for taxes - Stock Titan
Viatris (VTRS) director adds 26K shares via RSU vesting and grant - Stock Titan
Viatris (VTRS) executive Enrietti exercises RSUs, withholds shares for taxes - Stock Titan
Viatris (VTRS) director Mark W. Parrish reports RSU vesting and new equity award - Stock Titan
Viatris (VTRS) executive settles RSUs, receives new 56,727-unit award - Stock Titan
Viatris (VTRS) CEO boosts equity stake with RSU vesting and new award - Stock Titan
0.49%
1.92%
자본화:
|
볼륨(24시간):